Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 268,530,048
  • Shares Outstanding, K 1,767,110
  • Annual Sales, $ 56,197 M
  • Annual Income, $ 11,542 M
  • 60-Month Beta 0.83
  • Price/Sales 4.69
  • Price/Cash Flow 8.44
  • Price/Book 16.15
Trade ABBV with:

Options Overview Details

View History
  • Implied Volatility 25.77% ( -0.33%)
  • Historical Volatility 25.90%
  • IV Percentile 75%
  • IV Rank 58.57%
  • IV High 31.63% on 04/29/22
  • IV Low 17.49% on 08/31/21
  • Put/Call Vol Ratio 1.02
  • Today's Volume 20,665
  • Volume Avg (30-Day) 32,470
  • Put/Call OI Ratio 1.14
  • Today's Open Interest 426,005
  • Open Int (30-Day) 477,294

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate 3.43
  • Number of Estimates 7
  • High Estimate 3.52
  • Low Estimate 3.38
  • Prior Year 3.11
  • Growth Rate Est. (year over year) +10.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
139.93 +7.60%
on 04/29/22
159.50 -5.60%
on 04/27/22
-5.61 (-3.59%)
since 04/26/22
3-Month
139.93 +7.60%
on 04/29/22
175.91 -14.41%
on 04/08/22
+1.03 (+0.69%)
since 02/25/22
52-Week
105.56 +42.64%
on 09/20/21
175.91 -14.41%
on 04/08/22
+35.87 (+31.27%)
since 05/26/21

Most Recent Stories

More News
Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Media Release Copenhagen, Denmark, May 26, 2022 Multiple epcoritamab (DuoBody®-CD3xCD20) poster presentations highlighting data in a variety of...

0MGB.LN : 2,125.000 (unch)
GMAB : 29.81 (-0.63%)
ABBV : 150.57 (-0.91%)
Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating several investigational medicines in the company’s pipeline, or created using Genmab’s innovative drug development platforms,...

GMAB : 29.81 (-0.63%)
ABBV : 150.57 (-0.91%)
SGEN : 138.46 (+1.46%)
Amgen (AMGN) Ahead of Industry This Year So Far: What's Next?

Amgen's (AMGN) key drugs like Prolia, Repatha, Xgeva and biosimilars are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.

RHHBY : 43.3300 (+0.79%)
BMY : 77.59 (+0.45%)
AMGN : 253.05 (+0.02%)
ABBV : 150.57 (-0.91%)
3 Healthcare Stocks You Can Buy and Hold for the Next Decade

They're leaders in their fields.

VRTX : 269.65 (-0.44%)
ISRG : 223.30 (+0.32%)
ABBV : 150.57 (-0.91%)
SpringWorks (SWTX) Down Despite Desmoid Tumors Study Meeting Goal

SpringWorks' (SWTX) phase III study evaluating its investigational candidate, nirogacestat, in adult patients with progressing desmoid tumors, meets primary and key secondary endpoints.

REGN : 683.44 (-1.08%)
ABBV : 150.57 (-0.91%)
LPTX : 1.2000 (+0.84%)
SWTX : 30.83 (-5.63%)
2 Dividend Kings That Are Soundly Beating the Market in 2022

These stocks could be good places to park your money.

ABBV : 150.57 (-0.91%)
MO : 54.50 (+1.13%)
CLASS ACTION NOTICE: Kessler Topaz Meltzer & Check, LLP Reminds Investors that a Securities Fraud Class Action Lawsuit Has Been Filed Against AbbVie, Inc.

The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that the firm has filed a securities class action lawsuit against AbbVie, Inc. (AbbVie) ( NYSE: ABBV ) on behalf...

ABBV : 150.57 (-0.91%)
Why High Dividend ETFs are Beating the Market

We highlight 3 ETFs with juicy dividend yields and excellent performance

T : 21.32 (+0.09%)
MSFT : 265.90 (+1.29%)
CVX : 176.59 (+0.67%)
XOM : 96.64 (+0.35%)
ABBV : 150.57 (-0.91%)
FDL : 38.85 (+0.54%)
HDV : 108.70 (+0.68%)
DHS : 90.02 (+0.50%)
AAPL : 143.78 (+2.32%)
3 Great Dividend Stocks to Buy Now and Hold

The episode explores three strong dividend-paying stocks from three different areas of the economy that investors might want to consider buying during the market downturn and holding for the long run.

NEE : 75.04 (+0.33%)
UNP : 221.29 (+1.78%)
ABBV : 150.57 (-0.91%)
These 2 Numbers Could Spell Trouble for AbbVie Stock

The next few quarters could be a bumpy ride.

ABBV : 150.57 (-0.91%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi...

See More

Key Turning Points

3rd Resistance Point 154.97
2nd Resistance Point 154.02
1st Resistance Point 152.29
Last Price 150.57
1st Support Level 149.62
2nd Support Level 148.67
3rd Support Level 146.94

See More

52-Week High 175.91
Last Price 150.57
Fibonacci 61.8% 149.04
Fibonacci 50% 140.74
Fibonacci 38.2% 132.43
52-Week Low 105.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar